Lithium vs Lamotrigine for Bipolar Disorder: Which Protects Against What

Lithium and lamotrigine are both mood stabilizers for bipolar disorder, but they protect against different parts of the illness. Lithium is FDA-approved to treat acute manic and mixed episodes and for maintenance in bipolar I disorder, while lamotrigine is approved only for maintenance and is not recommended for treating an acute manic or mixed episode. In two 18-month maintenance trials that tested both against placebo, lithium's clearest benefit was against mania and lamotrigine's was against depression.

So the practical question is less "which is better" and more "which pole of your illness causes the most harm, and which monitoring and side effects can you live with." Lithium needs regular blood levels and kidney and thyroid checks; lamotrigine needs a slow start because of a rare but serious rash. Every decision to start, combine, switch or stop either medicine belongs with your prescriber.

Lithium and lamotrigine at a glance

For the wider field, including valproate and the antipsychotics approved for bipolar disorder, see bipolar disorder medications compared.

What lithium does well

Lithium is the only one of the two that treats an active manic episode as well as preventing new ones. In the pooled analysis of two 18-month maintenance trials, lithium was superior to placebo in delaying the time to intervention for mania, and in the analyses adjusted for the starting mood state, only lithium kept that advantage for mania. That is why lithium tends to come up first when manic episodes have been severe, dangerous or led to hospitalization.

The 2018 CANMAT and ISBD guidelines list lithium as a first-line option for acute mania, for bipolar I depression and for maintenance treatment, which no other single drug in this comparison matches.

The suicide-prevention evidence, read carefully

Lithium is often described as protective against suicide, and the evidence deserves a precise summary. A 2013 meta-analysis of 48 randomized trials found that lithium was more effective than placebo in reducing the number of suicides and deaths from any cause in people with mood disorders, though it did not show a clear benefit for deliberate self-harm. The authors concluded that lithium is an effective treatment for reducing suicide risk in mood disorders.

A later randomized trial in 519 veterans who had recently survived a suicide-related event tested adding lithium to usual care, and it found no overall difference in repeated suicide-related events; the trial was stopped for futility. Average lithium levels in that trial were below the usual maintenance target. The two findings are not contradictory so much as narrow: the trial suggests that simply adding lithium to an existing regimen is unlikely to prevent a broad range of suicide-related events, while the older evidence comes from long-term treatment of mood disorders. If suicidal thoughts are part of your history, tell your prescriber plainly; it is a legitimate factor in the choice, and safety planning matters regardless of which medicine you take.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

What lamotrigine does well

Lamotrigine's main strength is delaying the return of depression. In the same pooled analysis, lamotrigine was superior to placebo in delaying intervention for depression, and the authors concluded it was effective against both poles with more robust activity against depression. The FDA label reports the same pattern from its two pivotal trials: a statistically significant benefit over placebo for both depression and mania, with the finding more robust for depression.

Lamotrigine is also listed among the first-line options for bipolar I depression and for maintenance in the 2018 CANMAT and ISBD guidelines. Its limits are just as important: it does not treat an active manic episode, and effectiveness in the acute treatment of any mood episode has not been established. People whose illness is dominated by recurring depressions, rather than by severe mania, are the group for whom it most often makes sense. For the acute phase of bipolar depression, see bipolar depression treatment options.

Safety and side effects compared

Lithium

Lithium's boxed warning is about toxicity: the toxic range starts at 1.5 mEq/L, which is close to the therapeutic range of 0.8 to 1.2 mEq/L, and some people show toxic signs even within the usual range. Neurological signs range from fine tremor, lightheadedness and lack of coordination in milder cases to confusion, seizures, coma and death in severe ones, and nausea, vomiting and diarrhea can also occur. Fine hand tremor, frequent urination and thirst can appear when treatment starts and may persist. In the pooled maintenance trials, diarrhea and tremor were more common with lithium than with lamotrigine.

Over the long term, the label warns about reduced kidney concentrating ability, chronic kidney disease, underactive or overactive thyroid, and high calcium with overactive parathyroid glands, and it calls for monitoring of each. Risk of toxicity rises with dehydration, fever, heavy sweating, diarrhea, low-salt diets and kidney problems. Diuretics, NSAID pain relievers such as ibuprofen, blood pressure medicines that act on the renin-angiotensin system, and metronidazole can all raise lithium levels. The American Geriatrics Society advises older adults to avoid combining lithium with ACE inhibitors, ARBs or loop diuretics where possible because of toxicity risk, and to monitor levels when it cannot be avoided.

Lamotrigine

Lamotrigine's boxed warning covers serious rashes, including Stevens-Johnson syndrome, which occur in roughly 0.08% to 0.3% of adults taking it and more often in children. Nearly all life-threatening rashes have appeared within 2 to 8 weeks of starting, and the risk rises with taking valproate at the same time, exceeding the recommended starting dose or escalation schedule, or carrying the HLA-B*1502 gene variant. Because benign and dangerous rashes cannot be told apart reliably at first, the label says lamotrigine should ordinarily be stopped at the first sign of rash unless the rash is clearly unrelated.

Other label warnings include aseptic meningitis, a serious immune reaction called hemophagocytic lymphohistiocytosis, multiorgan hypersensitivity, blood count problems and suicidal thoughts. In 2021 the FDA reported that lamotrigine may increase the risk of serious heart rhythm problems in people with clinically important heart disease, and it told patients not to stop the medicine without first talking to their prescriber. The label lists heart failure, valvular or congenital heart disease, conduction disease, ventricular arrhythmias, Brugada syndrome and significant coronary disease among those conditions.

What living with each one involves

The full routine for lithium labs is covered in taking lithium: blood levels, kidney and thyroid monitoring.

Pregnancy and other special situations

Pregnancy planning can change the choice. The lithium label says early reports suggested an increase in heart malformations, especially Ebstein's anomaly, with first-trimester use, but later studies indicate the increased risk is likely small, and the data are insufficient to establish it. If lithium is continued in pregnancy, levels need monitoring and dose adjustment, and the label calls for lowering or pausing the dose two to three days before delivery. Estrogen changes lamotrigine levels, which is one reason dosing may need attention around contraception and pregnancy. These decisions are best made before conception with your prescriber and obstetric team; see psychiatric medications during pregnancy.

Lithium should be avoided in severe kidney impairment and started cautiously at lower doses in mild to moderate impairment. For someone with significant heart disease, the lamotrigine heart-rhythm warning becomes part of the discussion. For someone who cannot reliably get blood drawn or stay hydrated, lithium's monitoring needs weigh more heavily.

How prescribers often frame the choice

These are general patterns, not a substitute for an individual evaluation:

• Mania-dominant course, past hospitalizations for mania, or mania that needs treatment now: lithium, or another anti-manic medicine, is usually central, because lamotrigine does not treat acute mania.
• Depression-dominant course with milder or infrequent highs: lamotrigine is often considered for prevention, sometimes alongside another mood stabilizer.
• A history of suicide attempts: the lithium evidence is part of the conversation, along with therapy, safety planning and closer follow-up.
• Kidney disease or difficulty with regular blood tests: lithium may be harder to use safely.
• Recent valproate use or plans to start it: lamotrigine needs a different, slower schedule because valproate raises its levels and rash risk.

The two are also used together. Lamotrigine's pivotal trials allowed add-on use with other psychotropic medicines during titration, and the CANMAT and ISBD guidelines describe combination maintenance treatments among the first-line choices. Whether a second mood stabilizer is worth the added burden is a judgment for you and your prescriber to make together.

What the evidence does not tell you

• It does not say which drug will work for you. Response varies widely, and the trials report group averages.
• Lamotrigine's approval rests on bipolar I disorder; its role in bipolar II depends on clinical judgment and guideline recommendations rather than an FDA indication.
• The maintenance trials enrolled people who had already stabilized during an open-label phase, so they say less about people who never stabilize.
• No blood test predicts who will get lamotrigine rash, apart from the genetic factor named on the label.

If neither medicine has worked, or side effects have been hard to live with, a structured review can help; see getting a second opinion on your psychiatric medication.

Questions to ask your prescriber

• Looking at my history, which pole has caused more harm, and how does that shape your recommendation?
• What level are we aiming for on lithium, how often will labs be drawn, and who orders them?
• If I get a rash on lamotrigine, who do I call, and what happens after hours?
• Which of my current medicines, supplements or pain relievers interact with either drug?
• How would this plan change if I became pregnant or started or stopped birth control?
• What signs would tell us the medicine is not enough, and what would we add or try next?

Medication works best with therapy and early warning plans; the practice's page on early warning signs of a bipolar episode is a useful companion.

How this practice approaches mood stabilizer care

Ongoing care at the practice includes psychiatric evaluation and medication management, psychotherapy including CBT and DBT, and lab testing. The team includes psychiatrists and psychiatric nurse practitioners alongside psychotherapists. You can read about the practice's bipolar disorder treatment and medication management, and individual clinical care starts with the Patient Interest Form. Other decision guides are collected in Choosing Psychiatric Care.

Frequently asked questions

Can lamotrigine replace lithium if I hate the blood tests?

Sometimes, but not automatically. Lamotrigine does not treat an active manic episode, and in long-term trials against placebo lithium showed the clearer protection against mania. If mania has been a serious problem for you, a switch needs a careful plan with your prescriber rather than a simple swap.

Is lamotrigine a weaker drug than lithium?

Not weaker, but different. In placebo-controlled maintenance trials that included both, lamotrigine's benefit was clearest for delaying depression and lithium's for delaying mania; the trials were not designed to rank one drug over the other. Which matters more depends on your own pattern of episodes.

Do I need to change my lamotrigine dose if I start or stop birth control pills?

Possibly. Estrogen-containing pills can lower lamotrigine levels, and the label says maintenance doses often need adjusting when these pills are started or stopped. Tell your prescriber before you make the change.

Why does lamotrigine start at such a low dose?

Starting too high or increasing too fast raises the risk of serious rash. The label sets a fixed escalation schedule, and starter kits are designed to follow it for the first weeks.

Can I take ibuprofen while on lithium?

Ask first. NSAIDs such as ibuprofen and naproxen can raise lithium levels, so your prescriber may suggest an alternative or check a level.

Is lithium the same as the lithium sold as a supplement?

No. Prescription lithium carbonate is dosed to reach a measured blood level under medical supervision. Low-dose supplement products are a different thing and are not a substitute for prescribed treatment.

Sources

1. Lithium carbonate tablets and capsules prescribing information. DailyMed / U.S. FDA label (Hikma), 2026. dailymed.nlm.nih.gov
2. LAMICTAL (lamotrigine) prescribing information. DailyMed / U.S. FDA label (GlaxoSmithKline), 2025. dailymed.nlm.nih.gov
3. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Journal of Clinical Psychiatry (PubMed 15096085), 2004. pubmed.ncbi.nlm.nih.gov
4. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ (PubMed 23814104), 2013. pubmed.ncbi.nlm.nih.gov
5. Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder: A Randomized Clinical Trial. JAMA Psychiatry (PubMed 34787653), 2022. pubmed.ncbi.nlm.nih.gov
6. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders (PubMed 29536616), 2018. pubmed.ncbi.nlm.nih.gov
7. Lamictal (lamotrigine): Drug Safety Communication - Studies Show Increased Risk of Heart Rhythm Problems in Patients with Heart Disease. U.S. Food and Drug Administration, 2021. fda.gov
8. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society (PMC12478568), 2023. pmc.ncbi.nlm.nih.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.